Login to Your Account

Ampio Amps Up on Pain Findings in Knee Osteoarthritis

By Marie Powers
Staff Writer

Wednesday, August 14, 2013
Positive findings from an initial Phase III study of pain candidate Ampion drove shares of Ampio Pharmaceuticals Inc. (NYSE:AMPE) higher Wednesday. Patients in the Phase III SPRING study in osteoarthritis of the knee (OAK) treated with a single intra-articular injection of the non-steroidal immunomodulator achieved clinically meaningful reduction in pain.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription